Human vaccine development against Rift Valley fever

CEPI is pleased to announce the second phase of its call for proposals (CfP3ii) for the development of human vaccines against Rift Valley fever (RVF), which is co-funded by the European Union. Including USD 35 million (EUR 35 million) financial support provided by the European Union Horizon Europe programme, up to USD 50 million (EUR 50 million) in total will be made available by CEPI. Previous funding from CEPI is not a precondition for support. CEPI will support the following: a) GMP manufacture and release of clinical trial material, providing established release assays and production processes [...]